All In Biotech

Drug Trial Radar · NCT06221969

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,024 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,024

Actual

Start

Jan 16, 2024

Primary completion

Mar 4, 2026

Study completion Apr 6, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.

Conditions

  • Type 2 Diabetes

Interventions

  • CagrilintideDrug

    Cagrilintide will be administered subcutaneously.

  • SemaglutideDrug

    Semaglutide will be administered subcutaneously.

  • TirzepatideDrug

    Tirzepatide will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 68)
  2. Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)

Locations

197 sites in 8 countries. Site status is shown where the registry gives one.

  • Synexus Clin Res-Birmingham

    Birmingham, Alabama

  • Univ of Alabama_Birmingham

    Birmingham, Alabama

  • Prime Medical Group, LLC

    Gilbert, Arizona

  • Velocity Clinical Research-Phoenix

    Phoenix, Arizona

  • Synexus Rsch /Cnt Phnx Med C

    Phoenix, Arizona

  • Arkansas Clinical Research

    Little Rock, Arkansas

  • Unity Health-Searcy Medical Center

    Searcy, Arkansas

  • Velocity Clin Res-Chula Vista

    Chula Vista, California

  • Headlands Research California, LLC

    Escondido, California

  • Neighborhood Healthcare

    Escondido, California

  • St. Jude Heritage Yorba Linda - Pediatric Ste D

    Fullerton, California

  • Diabetes & Endocrine Specialists - La Mesa

    La Mesa, California

  • Diabetes and Endocrine Specialists - La Mesa

    La Mesa, California

  • Velocity Clin Res San Diego

    La Mesa, California

  • Headlands Research CTR Lincoln

    Lincoln, California

  • Loma Linda Univ Hlth Cr Endo

    Loma Linda, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Healthcare

    Palm Springs, California

  • Velocity Clin Res - Panorama

    Panorama City, California

  • Western University of Health Sciences

    Pomona, California

  • Endocrinology Josel Cabaccan

    San Jose, California

  • Mills-Peninsula Medical Center

    San Mateo, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Premier Medical Center, Inc.

    Toluca Lake, California

  • Velocity Clin Res - Panorama

    Van Nuys, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Optumcare Clinical Trials,LLC-Golden

    Colorado Springs, Colorado

  • Northeast Res Inst. Inc.

    Jacksonville, Florida

  • Bioclinical Research Alliance

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • South Broward Research LLC

    Miramar, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Optimal Research Sites

    Orange City, Florida

  • Trans Res Inst for Met & Diab

    Orlando, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Center for Diab,Obes & Metab

    Pembroke Pines, Florida

  • Hope Clin Res & Wellness

    Conyers, Georgia

  • Center for Adv Res & Education

    Gainesville, Georgia

  • Urban Family Practice Assoc

    Marietta, Georgia

Showing 40 of 197 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.